Supplements and Featured Publications
- 2025 Year in Review: Multiple Myeloma
2025 Year in Review: Multiple Myeloma
Key Takeaways
- Bispecific antibodies talquetamab and teclistamab show promise for advanced multiple myeloma, including extramedullary disease, with safe administration in community settings emphasized.
- CEPHEUS study highlights deep, durable responses in newly diagnosed, transplant-ineligible patients using a daratumumab-based regimen, with median PFS not reached after nearly five years.
Throughout 2025, data presented at major scientific conferences bolstered the case for the use of the bispecific antibodies talquetamab (Talvey) and teclistamab (Tecvayli) in later stage multiple myeloma, including for patients with extramedullary disease. Data and presentations outlined how to safely administer these therapies in a community setting. For newly diagnosed patients, data from CEPHEUS show patients not eligible for transplant who received a daratumumab-based regimen had deep and durable responses, with median progression-free survival (PFS) not reached after almost 5 years. And in November, FDA approved subcutaneous daratumumab (Darzalex Faspro) for patients with high-risk smoldering myeloma, based on the AQUILA trial.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
